Back to top
SESEN BIO, INC. (SESN)
(Delayed Data from NSDQ)
$1.30 USD
1.30
2,172,114
+0.07 (5.69%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.30 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.30 USD
+0.07 (5.69%)
Updated May 3, 2019 04:00 PM ET
After-Market: $1.30 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) COVID Pill Ineffective in Standard Risk Patients
by Zacks Equity Research
Pfizer (PFE) stops enrolling patients in a phase II/III study evaluating its COVID pill in standard-risk population after new data from this study showed that it is not all statistically significant.
Ionis' (IONS) Angelman Syndrome Drug Gets FDA's Orphan Tag
by Zacks Equity Research
The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.
Merck (MRK) Keytruda Adjuvant Lung Cancer sBLA Accepted by FDA
by Zacks Equity Research
The FDA is expected to give its decision on Merck's (MRK) Keytruda sBLA for adjuvant stage IB-IIIA NSCLC, following complete surgical resection, on Jan 29, 2023.
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
by Zacks Equity Research
ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.
FDA Committee Endorses bluebird's (BLUE) Thalassemia Therapy
by Zacks Equity Research
An FDA advisory committee favors approval for bluebird bio's (BLUE) beti-cel to treat transfusion-dependent thalassemia. A final decision by the regulatory body is expected on Aug 19, 2022.
Cogent (COGT) Surges on Robust Data from Mastocytosis Study
by Zacks Equity Research
Cogent's (COGT) bezuclastinib achieves robust effectiveness in patients with advanced systemic mastocytosis with a favorable safety and tolerability profile. Stock surges more than 58% on Jun 10.
GSK's RSV Vaccine Candidate Offers Robust Protection in Elderly
by Zacks Equity Research
GSK's RSV vaccine candidate for adults aged 60 years or above achieves statistically significant and clinically meaningful efficacy in a phase III study. Regulatory submissions are likely in the second half of 2022.
FDA Committee Recommends bluebird's (BLUE) CALD Therapy
by Zacks Equity Research
An FDA advisory committee supports approving bluebird bio's (BLUE) eli-cel for treating cerebral adrenoleukodystrophy. NASDAQ halts trading BLUE's common stock on Jun 9 and 10.
Vertex (VRTX) Kidney Drug Gets FDA Breakthrough Designation
by Zacks Equity Research
Vertex (VRTX) inaxaplin is being evaluated in a single-phase II/III pivotal study in patients with AMKD with two APOL1 mutations and proteinuric kidney disease.
bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
by Zacks Equity Research
Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.
Sanofi's (SNY) Dupixent Gets FDA Nod for Eczema in Infants
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron's label expansion application for Dupixent to include infants with moderate-to-severe atopic dermatitis gets FDA approval.
Biogen (BIIB) Inks Deal for Alectos' Parkinson's Disease Drug
by Zacks Equity Research
Biogen (BIIB) signs a deal with privately-held Alectos Therapeutics to gain an exclusive global license to the latter's pre-clinical oral selective GBA2 inhibitor, AL01811, targeting Parkinson's disease.
AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
by Zacks Equity Research
Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.
BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer
by Zacks Equity Research
Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.
Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug
by Zacks Equity Research
Repare Therapeutics (RPTX) signs a licensing agreement with Roche (RHHBY) to develop its lead candidate for solid tumor indications.
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
by Zacks Equity Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
by Zacks Equity Research
BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.
FDA Delays Decision on TGTX's BLA for Multiple Sclerosis Drug
by Zacks Equity Research
The FDA extends PDUFA date by three months on TG Therapeutics' (TGTX) regulatory submission for ublituximab for relapsing multiple sclerosis. Shares fell 14.5% following the announcement.
Biogen (BIIB), Denali Begin Mid-Stage Study on Parkinson's Drug
by Zacks Equity Research
Biogen (BIIB) and partner Denali initiate a mid-stage study to evaluate their oral LRRK2 inhibitor, BIIB122, in adults with early-stage Parkinson's disease. A late-stage study is planned to start later in 2022.
Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe
by Zacks Equity Research
Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.
Sanofi's (SNY) Dupixent Prurigo Nodularis NDA Gets Priority Tag
by Zacks Equity Research
The FDA grants priority review to Sanofi's (SNY) sBLA for Dupixent to include adults with prurigo nodularis, a chronic inflammatory skin disease.
Reata (RETA) Up More Than 12% YTD: What's Driving the Rally?
by Zacks Equity Research
Reata's (RETA) prospects are likely to improve following the potential approval of its lead candidate, omaveloxolone, expected by the end of 2022 is likely driving its share price.
Axcella (AXLA) Up on Decision to Prioritize Long-COVID Program
by Zacks Equity Research
Axcella (AXLA) re-prioritizes its clinical portfolio to focus on the development of AXA1125 targeting long COVID and NASH. It also suspends the development of AXA1665 to focus resources on AXA1125 studies.
Reata (RETA) Friedreich's Ataxia NDA Gets Priority Review
by Zacks Equity Research
Reata (RETA) is seeking approval for omaveloxolone as a treatment for neuromuscular disorder Friedreich's ataxia. The FDA grants priority review to the NDA for the same. Stock rises.
Esperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?
by Zacks Equity Research
Esperion's (ESPR) marketed drugs are the key drivers of the stock. Sales of the drugs increase more than 100% during the first quarter. Strong sales growth is expected to continue in 2022 as well as 2023.